(0.52%) 5 044.32 points
(0.59%) 38 126 points
(0.88%) 15 742 points
(-0.58%) $78.54
(4.66%) $2.02
(0.19%) $2 315.50
(0.59%) $26.91
(1.07%) $965.15
(0.22%) $0.935
(0.23%) $11.05
(0.26%) $0.801
(-1.41%) $91.94
1.77% $ 41.91
@ $45.58
Wydano: 14 vas. 2024 @ 16:32
Zwrot: -8.05%
Poprzedni sygnał: vas. 13 - 22:04
Poprzedni sygnał:
Zwrot: 1.54 %
Live Chart Being Loaded With Signals
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics...
Stats | |
---|---|
Dzisiejszy wolumen | 118 317 |
Średni wolumen | 718 311 |
Kapitalizacja rynkowa | 3.13B |
EPS | $0 ( 2024-03-05 ) |
Następna data zysków | ( $-0.530 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.38 |
ATR14 | $0.0910 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-01 | Hata Yujiro S | Buy | 480 000 | Stock Option (right to buy) |
2024-03-01 | Ruiz Briseno Andres | Buy | 85 000 | Stock Option (right to buy) |
2024-03-01 | Beaupre Darrin | Buy | 160 000 | Stock Option (right to buy) |
2024-03-01 | White Michael Anthony | Buy | 140 000 | Stock Option (right to buy) |
2024-03-01 | Throne Jason | Buy | 125 500 | Stock Option (right to buy) |
INSIDER POWER |
---|
41.90 |
Last 100 transactions |
Buy: 2 399 671 | Sell: 963 791 |
Wolumen Korelacja
IDEAYA Biosciences Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
IDEAYA Biosciences Inc Korelacja - Waluta/Towar
IDEAYA Biosciences Inc Finanse
Annual | 2023 |
Przychody: | $23.39M |
Zysk brutto: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2023 |
Przychody: | $23.39M |
Zysk brutto: | $19.38M (82.86 %) |
EPS: | $-1.960 |
FY | 2022 |
Przychody: | $50.93M |
Zysk brutto: | $48.83M (95.87 %) |
EPS: | $-1.320 |
FY | 2021 |
Przychody: | $27.94M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
IDEAYA Biosciences Inc
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej